|
|
Article: Angiotech's Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver[R] PTX[R] Stent.
- Article from:
- Blood Weekly
- Article date:
- August 27, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP) announced Cook Medical, a license holder of Angiotech's paclitaxel technology, reported CE Mark approval and limited commercial launch of the Zilver[R] PTX[R] Drug-Eluting Peripheral Stent in Europe. This approval represents a global landmark in bringing drug-eluting stent (DES) technology to people suffering from peripheral artery disease (PAD), a chronic disease affecting tens of millions of patients worldwide that is a leading cause of leg amputation and shortened lifespan (see also Angiotech Pharmaceuticals, Inc.).
"The awarding of the CE Mark is set to herald a revolution in the ...